Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Administrator Berwick Visits the Hill

This article was originally published in RPM Report

Executive Summary

Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.

You may also be interested in...



CMS News is Good for Troubled Markets

There was probably no group more relieved than the makers of implantable cardioverter defibrillators (ICDs) to see the Centers for Medicaid and Medicare Services (CMS) in August drastically modify its proposal to slash hospital reimbursement. The change is as a result of effective lobbying from the medical device community as well as the hospital industry, and is welcome news to all high-end device makers.

CMS Takes Sides in the Statin Wars

The Centers for Medicare & Medicaid Services is showing a lot more interest in ensuring broad access to low-cost generic drugs now that the agency is overseeing the implementation of Medicare Part D. As evidence of this trend, CMS considered weighing in on a court decision regarding the availability of Zocoor generics.

CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D

The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel